Business
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics from a boron chemistry platform across hematologic disease, infectious disease, and oncology.
AN2 Therapeutics remained pre-revenue, the net loss narrowed to $35.2M, and free cash flow improved to -$29.8M.
The read at a glance✓ Audited against SEC data
- Business mix — Boron-chemistry drug platformNote
- Revenue — No standard revenue fieldNote
- Profitability — Net loss narrowed 31.5%Note
- Cash — Free cash flow was -$29.8MWatch
- Balance sheet — Equity fell 35.2%Watch
- Insiders — 0 buys / 11 sellsWatch
- Accounting — Forensic screen unavailableNote
Leadership changes
From AN2 Therapeutics, Inc.'s own filings, the day they're filed.
- Sarah Williams · President · appointmenteff. 2026-02-01
- Lucy Day · Chief Financial Officer · appointmenteff. 2026-02-01
- Joshua Eizen · Chief Legal Officer · appointmenteff. 2024-11-04
Latest filings
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-06-09
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AN2 Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.